Title Credit Start and expiration dates Member price Non-member pricesort descending
Risk Factors & Potential Associated Causes of Developmental, Behavioral, & Mental Health Consequences in Children
1.0 NAPNAP contact hour. This presentation is designed for primary care APRNs to help them identify the children at risk and the red warning flags for DBMH diagnosis. It also provides critical information about the relationship between DBMH diagnosis and the dysregulated stress response system associated with ACES, trauma, and/or toxic stress. Participants will learn the valuable tools to discuss their concerns with the patients and their families, develop interventions, and prevention strategies.
    • 1.00 Contact hours
05/06/2019 to 05/31/2020 $0.00 $10.00
Child and Adolescent Pornography Exposure
JPHC CE 1.0 contact hour. Children and adolescents are growing up in a digital world. Adolescents are absorbed in the use of technology; however, this behavior is also becoming characteristic of younger children as well (Livingstone & Smith, 2014). One such risk is exposure to pornography. This continuing educational article will explore child and adolescent Internet pornography exposure in terms of definition, epidemiology, predictors, consequences, and implications for practice. J Pediatr Health Care. (2020) 34, 191−199
    • 1.00 Contact hours
01/30/2020 to 04/30/2021 $0.00 $10.00
JPHC CE: Common Skin Disorders in Pediatric Skin of Color
0.75 Contact Hour, 0.25 Pharmacology. Children with skin of color represent a large proportion of the pediatric population. There are numerous skin conditions that commonly occur in this population, including but not limited to acne, atopic dermatitis, pityriasis alba, tinea versicolor, progressive macular hypomelanosis, traction alopecia, and confluent and reticulated papillomatosis. This article highlights the clinical presentations of these conditions in skin of color and briefly addresses pathophysiology and treatment modalities. J Pediatr Health Care. (2019) Volume 33, Issue 6, pgs. 727-737.
    • 0.75 Contact hours
10/14/2019 to 12/31/2020 $0.00 $10.00
Management of Hypertension and the Use of Ambulatory Blood Pressure Monitoring
0.75 NAPNAP Contact Hour, 0.25 Pharmacology Hour This course will include prevalence and etiologies of high blood pressure in children and how to most accurately identify those patients who will require medical intervention. The presenters discussed evidence-based first and second line treatment, including recommended diagnostic and clinical monitoring. The role of the nurse practitioner in managing pediatric patients with concerns of high blood pressure will provide a unique view of changing practices.
    • 0.75 Contact hours
05/10/2019 to 06/30/2021 $5.00 $10.00
JPHC CE: Cafe au Lait Macules and Associated Genetic Syndromes
1.0 contact hours. Cafe au lait macules (CALMs) are a common, isolated dermatologic finding in the general population. But when do these irregularly shaped, jagged-edged, flat, hyperpigmented birthmarks suggest something that may warrant referral? Most pediatric providers are familiar with the association of CALMs and neurofibromatosis type 1. There are, however, other genetic conditions associated with these seemingly benign skin spots. This article provides an overview of CALMs, followed by a summary of several conditions associated with CALMs ranging from the most common(neurofibromatosis type 1) to rare, ring chromosome syndromes.It reviews the associated gene(s), pattern of inheritance, incidence, presenting symptoms, diagnosis, and management for these genetic conditions. J Pediatr Health Care. January/February (2020) 34, 71−81
    • 1.00 Contact hours
11/12/2019 to 02/28/2021 $0.00 $10.00
Concussion 2018
0.5 NAPNAP Contact Hour 0 Pharmacology Hours This course will discuss management of concussions.
    • 0.50 Contact hours
12/31/2018 to 12/31/2020 $5.00 $10.00
JPHC CE: Clinical Practice Recommendations for Pediatric Dyslipidemia
1.0 Contact Hours, 0.25 Pharmacology. The leading cause of mortality in the United States is atherosclerotic cardiovascular disease (ASCVD). Atherosclerotic lesions begin during childhood and can place individuals at greater risk for ASCVD. Providers play an active role in preventing the progression of risk factors and future ASCVD events through appropriate clinical management of genetic and acquired dyslipidemias in the pediatric population. Health care providers need to be aware of current recommendations related to screening for dyslipidemia, lifestyle modification strategies, pharmacologic treatment, and guidelines for ongoing monitoring. Most patients with mild to moderate dyslipidemia can be managed by a primary care provider.It is imperative that providers understand the pathophysiology, screening methods, and available treatment options to effectively manage the condition. Frequent reassessment of family history and adherence to lifestyle modifications and pharmacologic interventions is essential for effective treatment. Journal of Pediatric Health Care (2019) 33, volume 4, 494-504.
    • 1.00 Contact hours
06/13/2019 to 08/31/2020 $0.00 $10.00
JPHC CE: A Review on the Use of Cystic Fibrosis Transmembrane Conductance Regulator Gene Modulators in Pediatric Patients
1.0 contact hour of which 1.0 contain phamacology content. The literature surrounding the use of cystic fibrosis transmembrane conductance regulator-targeted pharmacotherapies in pediatric patients continues to evolve. These therapies represent a departure from symptom management and infection prevention, which have been the mainstay of cystic fibrosis management in pediatrics, to targeting the genetic defect present within these patients. This article reviews the clinical studies evaluating the safety and efficacy of ivacaftor, ivacaftor/lumacaftor, and ivacaftor/tezacaftor. These medications were initially studied in adults and adolescents but have begun to be studied in younger populations. Further investigation into the use of these drugs with different CFTR mutations and in younger age groups will continue to expand the number of patients who can benefit from these therapies. May–June, 2019 Volume 33, Issue 3, Pages 356–364
    • 1.00 Contact hours
04/18/2019 to 06/30/2020 $0.00 $10.00
Immunizations 2019: What NPs Who Care for Children Need to Know
1.0 NAPNAP Contact Hour 1.0 Pharmacology Hour Immunization recommendations are updated annually by the CDC. This course will advise NPs about the cutting edge issues in pediatric and adolescent immunizations. The recommended schedule, clarification of the guidelines, newly licensed vaccines and current controversies will be emphasized.
    • 1.00 Contact hours
04/24/2019 to 05/31/2020 $0.00 $10.00
Immunization Associated Pain Prevention
0.75 NAPNAP Contact Hour, 0.75 Pharmacology Hour Immunization associated pain prevention is a very important part of administering immunizations. With approximately 29 immunizations being administered to a child before the age of 6, learning how to control pain during these encounters is necessary to prevent both short-term and long-term sequelae associated with uncontrolled pain. This course will focus on various techniques to address immunization associated pain based on age and development.
    • 0.75 Contact hours
04/24/2019 to 05/31/2021 $5.00 $10.00
Chest Pain and Syncope 2018
The course will describe causes of chest pain and syncope. 0.5 NAPNAP Contact Hour 0 Pharmacology Hour
    • 0.50 Contact hours
12/31/2018 to 12/31/2020 $5.00 $10.00
Food Allergy prevention: Introducing allergens into an infant’s diet
1.0 NAPNAP contact hour. Food allergy is a hot topic and with a growing increase in its prevalence, parents and practitioners are concerned about the development of food allergies. New guidelines regarding the early introduction of peanuts to help reduce the incidence of peanut allergy were released in 2017. However, there is still confusion and uncertainty regarding these guidelines.  This webinar will provide the who, what, when, where and how to introduce peanuts into an infant’s diet.
    • 1.00 Contact hours
08/14/2019 to 09/04/2021 $0.00 $10.00
The Family Experience

This continuing education activity is administered by the National Association of Pediatric Nurse Practitioners (NAPNAP) as an Agency providing continuing education credit. Individuals who complete this program will be awarded 0.5 NAPNAP contact hours, of which 0.5 is pharmacology content/0.5 Psychopharmacology content.

    • 0.50 Contact hours
12/01/2019 to 12/31/2020 $5.00 $10.00
2019 Pediatric Rx, Module 4- GI Drugs

0.75 NAPNAP Contact Hour 0.75 Pharmacology Hours An extensive review will provide an up‐to‐date information on current recommendations for use of GI drugs in the pharmacological management of common GI pathologies in children.

    • 0.75 Contact hours
12/02/2019 to 11/30/2021 $7.50 $15.00
2019 Pediatric Rx, Module 6- Psychotropic Medications

0.75 NAPNAP Contact Hour 0.75 Pharmacology Hour 0.75 Psychopharmacology Hour An extensive review will provide the participant with up-to-date information about commonly used antidepressants and atypical antipsychotics.

    • 0.75 Contact hours
12/02/2019 to 11/30/2021 $7.50 $15.00

Pages